Kristensen GB - Search Results

1

Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy.

Greimel E, Kristensen GB, van der Burg ME, Coronado P, Rustin G, del Rio AS, Reed NS, Nordal RR, Coens C, Vergote I; European Organization for Research and Treatment of Cancer - Gynaecological Cancer Group and NCIC Clinical Trials Group. Greimel E, et al. Among authors: kristensen gb. Gynecol Oncol. 2013 Nov;131(2):437-44. doi: 10.1016/j.ygyno.2013.08.014. Epub 2013 Aug 27. Gynecol Oncol. 2013. PMID: 23994107 Clinical Trial.

2

The prognostic significance of stage, tumor size, cellular atypia and DNA ploidy in uterine leiomyosarcoma.

Nordal RR, Kristensen GB, Kaern J, Stenwig AE, Pettersen EO, Tropé CG. Nordal RR, et al. Among authors: kristensen gb. Acta Oncol. 1995;34(6):797-802. doi: 10.3109/02841869509127189. Acta Oncol. 1995. PMID: 7576748

3

The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer.

Makar AP, Baekelandt M, Tropé CG, Kristensen GB. Makar AP, et al. Among authors: kristensen gb. Gynecol Oncol. 1995 Feb;56(2):175-80. doi: 10.1006/gyno.1995.1027. Gynecol Oncol. 1995. PMID: 7896181

4

Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors.

Tropé C, Kaern J, Vergote IB, Kristensen G, Abeler V. Tropé C, et al. Gynecol Oncol. 1993 Nov;51(2):236-43. doi: 10.1006/gyno.1993.1279. Gynecol Oncol. 1993. PMID: 8276300 Review.

5

Is serum CA 125 at the time of relapse a prognostic indicator for further survival prognosis in patients with ovarian cancer?

Makar AP, Kristensen GB, Børmer OP, Tropé CG. Makar AP, et al. Among authors: kristensen gb. Gynecol Oncol. 1993 Apr;49(1):3-7. doi: 10.1006/gyno.1993.1076. Gynecol Oncol. 1993. PMID: 8482556

6

Serum CA 125 level allows early identification of nonresponders during induction chemotherapy.

Makar AP, Kristensen GB, Børmer OP, Tropé CG. Makar AP, et al. Among authors: kristensen gb. Gynecol Oncol. 1993 Apr;49(1):73-9. doi: 10.1006/gyno.1993.1089. Gynecol Oncol. 1993. PMID: 8482563

7

A phase II study of carboplatin and hexamethylmelamine as induction chemotherapy in advanced epithelial ovarian carcinoma.

Kristensen GB, Baekelandt M, Vergote IB, Tropé C. Kristensen GB, et al. Eur J Cancer. 1995 Oct;31A(11):1778-80. doi: 10.1016/0959-8049(95)00274-m. Eur J Cancer. 1995. PMID: 8541099 Clinical Trial.

8

The prognostic significance of surgery, tumor size, malignancy grade, menopausal status, and DNA ploidy in endometrial stromal sarcoma.

Nordal RR, Kristensen GB, Kaern J, Stenwig AE, Pettersen EO, Tropé CG. Nordal RR, et al. Among authors: kristensen gb. Gynecol Oncol. 1996 Aug;62(2):254-9. doi: 10.1006/gyno.1996.0224. Gynecol Oncol. 1996. PMID: 8751558

9

An evaluation of prognostic factors in uterine carcinosarcoma.

Nordal RR, Kristensen GB, Stenwig AE, Nesland JM, Pettersen EO, Trope CG. Nordal RR, et al. Among authors: kristensen gb. Gynecol Oncol. 1997 Dec;67(3):316-21. doi: 10.1006/gyno.1997.4875. Gynecol Oncol. 1997. PMID: 9441781

10

Immunohistochemical analysis of p53 protein in uterine sarcomas.

Nordal RR, Kristensen GB, Stenwig AE, Tropé CG, Nesland JM. Nordal RR, et al. Among authors: kristensen gb. Gynecol Oncol. 1998 Jul;70(1):45-8. doi: 10.1006/gyno.1998.5034. Gynecol Oncol. 1998. PMID: 9698472

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

257 results

Search Page